Dr Barbara Rolfe is a Senior Research Fellow and Associate Group Leader, at the Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland (UQ). Her research focuses on the role of myeloid cells and the innate immune system in responses to nanomaterials, wound healing and cancer. Specific areas of interest include biomedical applications of nanomaterials and how the immune response to nanoparticles influences in vivo fate, and the application of complement-targeting drugs as cancer therapeutics. In these areas, her work has advanced understanding of the contribution of myeloid cells to fibrotic tissue, mechanisms by which nanomaterials are taken up by cells, and the role of complement anaphylatoxins C3a and C5a in vascular disease and cancer; the latter leading to discovery of a previously unidentified role for C3a and its receptor (C3aR) in promoting tumour growth.